Hypoxia-inducible factor-1α restricts the anabolic actions of parathyroid hormone

Bone Research

Volumn 2, Issue , 2014, Pages

  Frey, Julie L ^a   Stonko, David P ^b   Faugere, Marie Claude ^b   Riddle, Ryan C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921772388     PISSN: 20954700     EISSN: 20956231     Source Type: Journal    
DOI: 10.1038/boneres.2014.5     Document Type: Article

References (59)

1. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709.
2. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 1994; 331: 1618-1623.
3. Hansen S, Hauge EM, Beck Jensen JE, Brixen K. Differing effects of PTH1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT. J Bone Miner Res 2013; 28: 736-745.
4. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85: 3069-3076.
5. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007; 40: 1434-1446.
6. Abou-Samra AB, Juppner H, Force T, et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 1992; 89: 2732-2736.
7. Iida-Klein A, ZhouH, Lu SS, et al. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. J BoneMiner Res 2002; 17: 808-816.
8. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138: 4607-4612.
9. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446.
10. Wu X, Pang L, Lei W, et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010; 7: 571-580.
11. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995; 136: 3632-3638.
12. Rodan SB, Rodan GA. The effect of parathyroid hormone and thyrocalcitonin on the accumulation of cyclic adenosine 39:59-monophosphate in freshly isolated bone cells. J Biol Chem 1974; 249: 3068-3074.
13. Wang Y, Nishida S, Boudignon BM, et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007; 22: 1329-1337.
14. Yakar S, Bouxsein ML, Canalis E, et al. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006; 189: 289-299.
15. Yamaguchi M, Ogata N, Shinoda Y, et al. Insulin receptor substrate-1 is required for bone anabolic function of parathyroid hormone in mice. Endocrinology 2005; 146: 2620-2628.
16. Qiu T, Wu X, Zhang F, Clemens TL, Wan M, Cao X. TGF-beta type II receptor phosphorylates PTH receptor to integrate bone remodelling signalling. Nat Cell Biol 2010; 12: 224-234.
17. Li C, Xing Q, Yu B, et al. Disruption of LRP6 in osteoblasts blunts the bone anabolic activity of PTH. J Bone Miner Res 2013; 28: 2094-2108.
18. Robling AG, Kedlaya R, Ellis SN, et al. Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone-A nd envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 2011; 152: 2963-2975.
19. Robling AG, Childress P, Yu J, et al. Nmp4/CIZ suppresses parathyroid hormone-induced increases in trabecular bone. J Cell Physiol 2009; 219: 734-743.
20. Childress P, Philip BK, Robling AG, et al. Nmp4/CIZ suppresses the response of bone to anabolic parathyroid hormone by regulating both osteoblasts and osteoclasts. Calcif Tissue Int 2011; 89: 74-89.
21. Semenza GL. Hypoxia-inducible factors in physiology andmedicine. Cell 2012; 148: 399-408.
22. Semenza GL. HIF-1, O2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus. Cell 2001; 107: 1-3.
23. Mole DR, Blancher C, Copley RR, et al. Genome-wide association of hypoxia-inducible factor (HIF)-1a and HIF-2a DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009; 284: 16767-16775.
24. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27: 1859-1867.
25. Shomento SH, Wan C, Cao X, et al. Hypoxia-inducible factors 1a and 2a exert both distinct and overlapping functions in long bone development. J Cell Biochem 2010; 109: 196-204.
26. Wang Y, Wan C, Deng L, et al. The hypoxia-inducible factor a pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest 2007; 117: 1616-1626.
27. Riddle RC, Leslie JM, Gross TS, Clemens TL. Hypoxia-inducible factor-1a protein negatively regulates load-induced bone formation. J Biol Chem 2011; 286: 44449-44456.
28. Akeno N, Robins J, Zhang M, Czyzyk-Krzeska MF, Clemens TL. Induction of vascular endothelial growth factor by IGF-I in osteoblastlike cells is mediated by the PI3K signaling pathway through the hypoxiainducible factor-2a. Endocrinology 2002; 143: 420-425.
29. Niziolek PJ, Murthy S, Ellis SN, et al. Rapamycin impairs trabecular bone acquisition from high-dose but not low-dose intermittent parathyroid hormone treatment. J Cell Physiol 2009; 221: 579-585.
30. Prisby R, GuignandonA, Vanden-BosscheAet al. Intermittent PTH(1-84) is osteoanabolic but not osteoangiogenic and relocates bone marrow blood vessels closer to bone-forming sites. J BoneMiner Res 2011; 26: 2583-2596.
31. Zhang M, Xuan S, Bouxsein ML, et al., Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002; 277: 44005-44012.
32. Ryan HE, Lo J, Johnson RS. HIF-1a is required for solid tumor formation and embryonic vascularization. EMBO J 1998; 17: 3005-3015.
33. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2a results in anemia. Proc Natl Acad Sci USA 2007; 104: 2301-2306.
34. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci USA 2001; 98: 1583-1588.
35. Lang CH, Frost RA, Bronson SK, Lynch CJ, Vary TC. Skeletal muscle protein balance in mTOR heterozygous mice in response to inflammation and leucine. Am J Physiol Endocrinol Metab 2010; 298: E1283-E1294.
36. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 2010; 25: 1468-1486.
37. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2013; 28: 2-17.
38. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610.
39. Land SC, Tee AR. Hypoxia-inducible factor 1a is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007; 282: 20534-20543.
40. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014.
41. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F. Wnt/betacatenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 2002; 22: 1172-1183.
42. Milkiewicz M, Doyle JL, Fudalewski T, Ispanovic E, Aghasi M, Haas TL. HIF-1a and HIF-2a play a central role in stretch-induced but not shearstress-induced angiogenesis in rat skeletal muscle. J Physiol 2007; 583: 753-766.
43. Liu XH, Kirschenbaum A, Lu Met al. Prostaglandin E2 induces hypoxiainducible factor-1a stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 2002; 277: 50081-50086.
44. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64: 993-998.
45. Semenza GL. HIF-1 and human disease: One highly involved factor. Genes Dev 2000; 14: 1983-1991.
46. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulin-like growth factor 2. Cancer Res 1999; 59: 3915-3918.
47. Yamashita R, Suzuki Y, Takeuchi N, et al. Comprehensive detection of human terminal oligo-pyrimidine (TOP) genes and analysis of their characteristics. Nucleic Acids Res 2008; 36: 3707-3715.
48. Blancquaert S, Wang L, Paternot S, et al. cAMP-dependent activation of mammalian target of rapamycin (mTOR) in thyroid cells. Implication in mitogenesis and activation of CDK4. Mol Endocrinol 2010; 24: 1453-1468.
49. Alam H, Maizels ET, Park Y, et al. Follicle-stimulating hormone activation of hypoxia-inducible factor-1 by the phosphatidylinositol 3-kinase/AKT/Ras homolog enriched in brain (Rheb)/mammalian target of rapamycin (mTOR) pathway is necessary for induction of select protein markers of follicular differentiation. J Biol Chem 2004; 279: 19431-19440.
50. Brugarolas J, Lei K, Hurley RL, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18: 2893-2904.
51. Simon MC. Mitochondrial reactive oxygen species are required for hypoxic HIF a stabilization. Adv Exp Med Biol 2006; 588: 165-170.
52. Brunelle JK, Bell EL, Quesada NM, et al. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab 2005; 1: 409-414.
53. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3: 177-185.
54. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulatingmitochondrial oxygen consumption. Cell Metab 2006; 3: 187-197.
55. Wong CC, Zhang H, Gilkes DM, et al. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012; 90: 803-815.
56. LeeK, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009; 106: 17910-17915.
57. Zhang H, Qian DZ, Tan YS, et al. Digoxin and other cardiac glycosides inhibitHIF-1A synthesis and block tumor growth. Proc Natl Acad Sci USA 2008; 105: 19579-19586.
58. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006; 7: 113-121.
59. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003; 19: 415-432.